NeoLNP? mRNA Transfection Vector Set (T cells Special) represents a groundbreaking innovation by Scindy Pharmaceutical, built upon cutting-edge lipid nanoparticle (LNP) technology, tailored exclusively for the transfection of T cells. This new generation of patented transfection vector set embodies the following key features:

• Groundbreaking LNP Technology: Our NeoLNP? mRNA Transfection Vector Set (T cells Special) is built upon the our patented LNP technology which has realized the extraordinary transfection performance for T cells.
• Outstanding Cytoplasmic Delivery: Leveraging the unique transmembrane transport and endosomal excape mechanisms, NeoLNP? mRNA Transfection Vector Set (T cells Special) conducts highly efficient cytoplasmic delivery, releasing the huge potential of T cell therapeutics.
• Excellent Safety and Minimal Cytotoxicity: NeoLNP? utilizes the biodegradable ionizable cationic lipid which can be fast metabolized upon cellular internalization. Particularly, the alcohol-free formulation avoids the unneccesary harmness of conventional LNP products, guaranteeing the excellent safety of NeoLNP? mRNA Transfection Vector Set (T cells Special).
• Highly Efficient Gene Translation: NeoLNP? realizes the efficient expression of target proteins, making it a powerful tool in gene translation studies.
• Minimized Pre-Treatment of T cells: NeoLNP? minimizes the required pre-treatment of T cells, simplifying the process for you.

Jurkat Cell Transfection

In a 24-well plate, 0.5 μg and 1.0 μg of EGFP mRNA were transfected into Jurkat cells using the NeoLNP? mRNA transfection vector set designed for T cells. At 24 hours post-transfection, cell viability was assessed through fluorescence microscopy. The results revealed that the expression efficiency of GFP protein in Jurkat cells exceeded 90%, and the cell viability was over 95%. These results provided further evidence on the exceptional efficacy and safety of the NeoLNP? mRNA transfection vector set.

Excellent Transfection Effeciency in Human Primary T Cells

In a 24-well plate, 0.5 μg of EGFP mRNA was introduced into human primary T cells by using the NeoLNP? mRNA transfection vector set designed specifically for T cells. Flow cytometry was employed to assess transfection efficiency and cellular viability at 24 hours post-transfection. The findings revealed a cell viability exceeding 90% and a GFP positivity rate reaching 80%. These outcomes provided further substantiation of the robust efficacy and safety profile inherent to the NeoLNP? mRNA transfection vector set.